A trial shows that semaglutide stops fat accumulation and liver fibrosis in a disease associated with metabolic dysfunction ...

Metabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four people worldwide. Once called non-alcoholic fatty liver disease, this condition ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH) ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.Results from the ESSENCE phase 3 clinical trial ...